STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

Data ReadoutpositivePositive

AI Analysis

Summary

Life Biosciences shared a glaucoma study update showing three patients received a single injection of its experimental cellular reprogramming drug with no serious adverse events reported.

Clinical Trial Data

Patients

Outcome Details

Three glaucoma patients received single injection with no serious adverse events

Importance:4/10

Sentiment:

0.60

cellular reprogrammingglaucomaclinical trial updatesafety

Read the original article

Published by STAT News on October 9, 2026 3:41 PM

Read Original